186 related articles for article (PubMed ID: 37966715)
1. Plant virus-derived nanoparticles decorated with genetically encoded SARS-CoV-2 nanobodies display enhanced neutralizing activity.
Merwaiss F; Lozano-Sanchez E; Zulaica J; Rusu L; Vazquez-Vilar M; Orzáez D; Rodrigo G; Geller R; Daròs JA
Plant Biotechnol J; 2024 Apr; 22(4):876-891. PubMed ID: 37966715
[TBL] [Abstract][Full Text] [Related]
2. Production of Potyvirus-Derived Nanoparticles Decorated with a Nanobody in Biofactory Plants.
Martí M; Merwaiss F; Butković A; Daròs JA
Front Bioeng Biotechnol; 2022; 10():877363. PubMed ID: 35433643
[TBL] [Abstract][Full Text] [Related]
3. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
[TBL] [Abstract][Full Text] [Related]
4. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
[TBL] [Abstract][Full Text] [Related]
5. Nanobody engineering for SARS-CoV-2 neutralization and detection.
Hannula L; Kuivanen S; Lasham J; Kant R; Kareinen L; Bogacheva M; Strandin T; Sironen T; Hepojoki J; Sharma V; Saviranta P; Kipar A; Vapalahti O; Huiskonen JT; Rissanen I
Microbiol Spectr; 2024 Apr; 12(4):e0419922. PubMed ID: 38363137
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of nanobodies neutralizing SARS-CoV-2 variants.
Shi Z; Li X; Wang L; Sun Z; Zhang H; Chen X; Cui Q; Qiao H; Lan Z; Zhang X; Li X; Li L; Xu J; Gong R; Fan C; Geng Y
Structure; 2022 May; 30(5):707-720.e5. PubMed ID: 35276082
[TBL] [Abstract][Full Text] [Related]
7. Viral nanoparticles for in vivo tumor imaging.
Wen AM; Lee KL; Yildiz I; Bruckman MA; Shukla S; Steinmetz NF
J Vis Exp; 2012 Nov; (69):e4352. PubMed ID: 23183850
[TBL] [Abstract][Full Text] [Related]
8. A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals.
Wu P; Yang Q; Zhao X; Liu Q; Xi J; Zhang F; He J; Yang H; Zhang C; Ma Z; Deng X; Wang Y; Chen C
Res Vet Sci; 2022 Jul; 145():46-49. PubMed ID: 35152188
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies.
Kaewchim K; Glab-Ampai K; Mahasongkram K; Saenlom T; Thepsawat W; Chulanetra M; Choowongkomon K; Sookrung N; Chaicumpa W
Viruses; 2023 May; 15(6):. PubMed ID: 37376552
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
[TBL] [Abstract][Full Text] [Related]
11. Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein.
Su Q; Shi W; Huang X; Wan Y; Li G; Xing B; Xu ZP; Liu H; Hammock BD; Yang X; Yin S; Lu X
Cells; 2022 Oct; 11(21):. PubMed ID: 36359751
[TBL] [Abstract][Full Text] [Related]
12. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
13. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.
Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L
Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063
[TBL] [Abstract][Full Text] [Related]
14. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
15. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
16. Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift.
Laroche A; Orsini Delgado ML; Chalopin B; Cuniasse P; Dubois S; Sierocki R; Gallais F; Debroas S; Bellanger L; Simon S; Maillère B; Nozach H
MAbs; 2022; 14(1):2076775. PubMed ID: 35593235
[TBL] [Abstract][Full Text] [Related]
17. Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization.
Yang J; Lin S; Chen Z; Yang F; Guo L; Wang L; Duan Y; Zhang X; Dai Y; Yin K; Yu C; Yuan X; Sun H; He B; Cao Y; Ye H; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
PLoS Pathog; 2023 Nov; 19(11):e1011804. PubMed ID: 38033141
[TBL] [Abstract][Full Text] [Related]
18. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
[TBL] [Abstract][Full Text] [Related]
19. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
20. Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis.
Zupancic JM; Desai AA; Schardt JS; Pornnoppadol G; Makowski EK; Smith MD; Kennedy AA; Garcia de Mattos Barbosa M; Cascalho M; Lanigan TM; Tai AW; Tessier PM
Cell Chem Biol; 2021 Sep; 28(9):1379-1388.e7. PubMed ID: 34171229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
